Table of Contents

company-logo

CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product candidate that is in pivotal Phase II trial for the treatment of relapsed/refractory multiple myeloma in China; CT041, an autologous CAR-T product candidate that is in Phase Ib/II clinical trial for advanced gastric/gastroesophageal junction cancer and pancreatic cancer in China, as well as in Phase Ib clinical trial for advanced gastric or pancreatic cancer in the United States; and CT011, an autologous CAR-T product candidate that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, an autologous CAR-T products candidate that is in Phase I/II clinical trial for the treatment of B cell Non-Hodgkin's lymphoma in China; AB011, a humanized monoclonal antibody product candidate that is in Phase I clinical trial for the treatment of CLDN18.2 positive solid tumors in China; and CT017, an autologous Glypican-3-targeted CAR-T product candidate for the treatment of hepatocellular carcinoma, as well as other product candidates for the treatment of solid tumors. The company was founded in 2014 and is headquartered in Shanghai, China.

CARsgen Therapeutics Dividend Announcement

• CARsgen Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on CARsgen Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

CARsgen Therapeutics Dividend History

CARsgen Therapeutics Dividend Yield

CARsgen Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing CARsgen Therapeutics stock? Use our calculator to estimate your expected dividend yield:

CARsgen Therapeutics Financial Ratios

P/E ratio-12944.22
PEG ratio223.92
P/B ratio2.97
ROE-0.02%
Payout ratio0.00%
Current ratio9.47
Quick ratio9.44
Cash Ratio9.00

CARsgen Therapeutics Dividend FAQ

Does CARsgen Therapeutics stock pay dividends?
CARsgen Therapeutics does not currently pay dividends to its shareholders.
Has CARsgen Therapeutics ever paid a dividend?
No, CARsgen Therapeutics has no a history of paying dividends to its shareholders. CARsgen Therapeutics is not known for its dividend payments.
Why doesn't CARsgen Therapeutics pay dividends?
There are several potential reasons why CARsgen Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will CARsgen Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While CARsgen Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is CARsgen Therapeutics a dividend aristocrat?
CARsgen Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is CARsgen Therapeutics a dividend king?
CARsgen Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is CARsgen Therapeutics a dividend stock?
No, CARsgen Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy CARsgen Therapeutics stocks?
To buy CARsgen Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy CARsgen Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.